Inroads to Anastomosis for Surgical Coronary Revascularization
This article was originally published in Start Up
Executive Summary
For emerging device companies, the course of success in coronary surgery markets never did run smooth, but progress in anastomosis devices has been particularly halting. That's not to say that start-ups can't make it here, though. Cardica is making inroads to the market, and Health Research International, in its recent report, "US Opportunities in Surgical Coronary Revascularization," which forecasts a 14% growth rate in the market over the next several years, identifies several young companies with promising devices in development.
You may also be interested in...
Start-Up News June 2007
New incubators are helping to fill a resource gap between universities looking for homes for their early stage medical device technologies and individual entrepreneurs looking to move their innovative projects out of the garage.
Start-Up News June 2007
New incubators are helping to fill a resource gap between universities looking for homes for their early stage medical device technologies and individual entrepreneurs looking to move their innovative projects out of the garage.
Magenta Medical Corp.
Magenta Medical is developing a device that provides hemostasis during minimally-invasive off pump coronary artery bypass graft surgery, without the use of an aortic clamp. Its founder is Dartmouth interventional cardiologist-entrepreneur Aaron Kaplan, whose previous start-ups include LocalMed and Perclose.